Regeneron Pharmaceuticals Inc. buy SVB Leerink LLC
Start price
28.03.23
/
50%
€753.50
Target price
28.03.24
-
Performance (%)
19.76%
End price
29.03.24
€902.40
Summary
This prediction ended on 29.03.24 with a price of €902.40. The BUY prediction by SVB_Leerink_LLC finished with a performance of 19.76%. SVB_Leerink_LLC has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Regeneron Pharmaceuticals Inc. | -3.315% | -3.315% | 30.774% | -14.953% |
| iShares Core DAX® | 2,55 % | 0,56 % | 14,14 % | 49,14 % |
| iShares Nasdaq 100 | 2,74 % | -0,60 % | 30,37 % | 82,05 % |
| iShares Nikkei 225® | 6,58 % | 4,34 % | 49,37 % | 60,62 % |
| iShares S&P 500 | 1,93 % | -0,51 % | 24,26 % | 59,66 % |
Comments by SVB_Leerink_LLC for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) was upgraded by analysts at SVB Leerink LLC from a "market perform" rating to an "outperform" rating.
Ratings data for REGN provided by MarketBeat
In the thread Trading Regeneron Pharmaceuticals Inc.
Die von SVB_Leerink_LLC gewählte maximale Laufzeit wurde überschritten